Viewing data from:

ACYCLOVIR SODIUM

ANDA

ACYCLOVIR SODIUM | A074596 | CHARTWELL INJECTABLES LLC

2 strengths0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Acyclovir Sodium (2023)

Total Spending

$47K

Total Claims

234

Beneficiaries

103

Avg Cost/Unit

$1.13

Spending Trend

$63K(2019)→$53K(2020)→$36K(2021)→$55K(2022)→$47K(2023)

YoY Change:+14.9%

5yr CAGR:+9.0%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs

3 active API suppliers hold Drug Master Files for this ingredient.

EXCELLA GMBH AND CO KGACYCLOVIR SODIUM

DMF 109451994

SOLARA ACTIVE PHARMA SCIENCES LTDACYCLOVIR SODIUM

DMF 242892010

RAJASTHAN ANTIBIOTICS LTDACYCLOVIR SODIUM (STERILE)

DMF 408662024

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 1GM BASE/VIAL

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Apr 22, 1997

No patent or exclusivity listings for this strength.

#002 — EQ 500MG BASE/VIAL

0 patents0 exclusivities▾

INJECTABLE;INJECTION | Approved: Apr 22, 1997